Clinical effects of trithiozine, a newer gastric anti-secretory agent.

Abstract

Trithiozine is a new product which in animal studies proved to have a marked anti-secretory and anti-ulcer effect, along with a very low acute and chronic toxicity and no ganglioplegic, anticholinergic and anti-H2 activity. Clinical trials with trithiozine have been performed in some European countries. The results of these trials, most of which were conducted on a double-blind basis, and including already several hundreds of patients, have shown that oral trithiozine: exerts a very significant action on both basal and stimulated gastric acid secretion, without a rebound hypersecretion; promotes, in most patients, a complete endoscopic healing of peptic ulcer, in addition to an early symptomatic relief; has a mild sedative action; does not affect the pancreatic secretion; is well tolerated even for long-term (up to 10 months) treatments.

• Authors: R Pellegrini
• Journal: The Journal of international medical research (J Int Med Res) Vol. 7 Issue 5 Pg. 452-8 ( 1979) ISSN: 0300-0605 [Print] England
• PMID: 387498 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Review)

Chemical References

• Anti-Ulcer Agents
• Morpholines
• Placebos
• Propantheline
• Cimetidine

Topics

• Anti-Ulcer Agents (administration & dosage, adverse effects, therapeutic use)
• Cimetidine (therapeutic use)
• Clinical Trials as Topic
• Depression, Chemical
• Double-Blind Method
• Gastric Juice (metabolism)
• Humans
• Morpholines (administration & dosage, adverse effects, therapeutic use)
• Peptic Ulcer (drug therapy)
• Placebos
• Propantheline (therapeutic use)